ERT and Endometrial Cancer Survivors
ACOG NEWS RELEASEEmbargoed until March 31, 2001
Another barrier was broken.
5:00 PM EST
ERT and Endometrial Cancer Survivors
WASHINGTON, DC — Use of estrogen replacement therapy (ERT), with or without progestins, among women diagnosed with endometrial cancer does not appear to increase their risk of recurring cancer or death, says new research from the University of California-Irvine. ERT for women with a history of endometrial cancer remains controversial. Physicians have historically withheld ERT from these patients based on the theoretical risk that estrogen may stimulate a recurrence of cancer. But, according to research in the April issue of Obstetrics & Gynecology, women who received estrogen replacement therarpy (ERT) after their cancer treatments remained disease-free significantly longer than a group of similar women who did not receive ERT. Endometrial cancer, the fourth most common cancer in American women, has an overall cure rate of over 70 percent.
Contact: Philip J. DiSaia, MD, University of California, Irvine Medical Center, Orange, CA, at pjdisaia@uci.edu.
# # #
Studies published in Obstetrics & Gynecology, the peer-reviewed scientific journal of The American College of Obstetricians and Gynecologists (ACOG), do not necessarily reflect the policies or opinions of ACOG. The American College of Obstetricians and Gynecologists is the national medical organization representing nearly 40,000 physicians who provide health care for women.
Copyright © 2003 The American College of Obstetricians and Gynecologists
409 12th Street, SW, Washington, DC 20024-2188